Louvain-La-Neuve, Belgium, 27 August 2015 - IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, today announces its consolidated results for the first half of 2015.

Business Highlights

Strong Proton Therapy and Other Accelerators order intake in H1, up 86% to EUR 110 million from the same period in 2014, comprising three Proteus®ONE* and three Proteus®PLUS systems and six accelerators

Record period-end backlog for Proton Therapy and Other Accelerators of EUR 303.2 million, up 56% YoY, 25% of which is Proteus®ONE orders, demonstrating the growing importance of single room compact solutions where IBA has a unique competitive advantage

Steadily growing Proton Therapy Services backlog to be recognized over time, now amounting to EUR 506.6 million, up 24% YoY due to the strong capture rate with new equipment orders

Dosimetry continues to show strongly improved performance with revenues growing 19.3% to EUR 26.8 million compared to EUR 22.5 million in the same period last year and backlog remaining strong at EUR 17.8 million

Philips collaboration bearing fruit with three Proteus®ONE orders signed in the UK with Proton Partners International

Strategic alliance signed with Toshiba Corporation for Proteus®ONE in Japan and advancing carbon therapy in the rest of the world

Financial Highlights

Total Group revenue of EUR 121.0 million for the first six months of 2015, up 23.3% (H1 2014: EUR 98.2 million)

REBIT up 30.8% to EUR 12.6 million with margin at 10.4%, in line with guidance

Reported net profit of EUR 14.4 million, up by 94.2% YoY with margin increase to 11.9% from 7.6%

2015 top line guidance increased from "above 10%" to 15-20% revenue growth for the year

Post Period End Highlight

Completion of the divestiture of IBA Molecular North America, Inc. (IBAM NA) to Illinois Health and Science (IHS). The transaction is not expected to have a significant impact on IBA's 2015 P&L but will generate cash proceeds of approximately EUR 10 million for IBA during the third quarter of 2015

Olivier Legrain, Chief Executive Officer of IBA, commented: "IBA has had a strong first half underpinned by a very buoyant global proton therapy environment. As the only company in the world able to convincingly offer both multi-room and compact single-room proton therapy systems, I am pleased to see that both solutions have seen such strong performance despite growing competition, demonstrating the broad appeal of IBA's proton therapy offering.

More HCB News